-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5197 FLT3 Inhibitors As Maintenance Therapy Post Allogenic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients with FLT3 Mutations; A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts
Session: 908. Outcomes Research: Myeloid Malignancies: Poster III
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, Adult, Elderly, Clinical Research, Diseases, Treatment Considerations, Myeloid Malignancies, Study Population, Human
Monday, December 9, 2024, 6:00 PM-8:00 PM

Sadia Ansar1*, Mahnoor Asghar Keen, MD, MBBS2*, Mahnoor Sukaina, MBBS3*, Muhammad Saeed, MBBS4*, Zarlish Rehman, MD, MBBS2*, Roshaan Rehman, MBBS5*, Qazi Muhammad Farooq Wahab, MD, MBBS2*, Faryal Masaud, MBBS2*, Aqsa Mumtaz, MD, MBBS6*, Karan Jatwani, MD, MBBS7* and Muhammad Salman Faisal, MD, MBBS8

1Rawal Institute of Health Sciences, Islamabad, Pakistan
2Khyber Medical College, Peshawar, Pakistan
3Karachi Medical and Dental College, Karachi, Pakistan
4D.G. Khan Medical College, Dera Ghazi Khan, Pakistan
5Kabir Medical College, Peshawar, Pakistan
6Montefiore St. Luke's Cornwall, Newburgh, NY
7Assistant Professor, Department of Hematology Oncology, George Washington University, Washington DC
8University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK

INTRODUCTION:

Approximately 20-30% of adult patients with acute myeloid leukemia (AML) have an FMS-like tyrosine kinase 3 (FLT3) mutation, which falls in the intermediate risk category for relapse and overall survival per ELN 2022 classification, and eligible patients undergo allogeneic hematopoietic cell transplantation (allo-HCT). FLT3 inhibitors (FLT3i) are used in induction and relapsed settings, but recent studies suggest that FLT3i may reduce the risk of post-transplant relapse. We performed this systematic review and meta-analysis to evaluate the efficacy of FLT3i as post-transplant maintenance therapy in AML patients.

METHODS:

A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Clinicaltrials.gov from inception to March 29, 2024. Studies were included that evaluated response [overall survival (OS), relapse-free survival (RFS), and leukemia-free survival (LFS)], in comparisons between FLT3i and control groups. RevMan version 5.4.1 was used for statistical analysis. A random effect model with inverse variance as the statistical method was used for hazard ratio (HR) and 95% confidence interval (CI).

RESULTS:

Of 1698 included studies, the data consists of 13 observational studies, comprising 4402 patients (52% males and 48% females), who met the inclusion criteria. Of the sample size, 36% of patients received FLT3i therapy, while the control group comprised 63.9% of patients. Patient age ranged from 14 to 78 years (median 49 years in intervention). AML subtypes included de novo (29%), secondary to antecedent hematological disorder (AHD) (1.7%), secondary to therapy (0.8%), and unspecified (68.5%). The follow-up period extended from 5.7 to 47.7 months. Nine out of thirteen studies reported cytogenetic risk. The type of FLT3i regimen used was reported as 54% Sorafenib followed by 15% Midostaurin, and only 8% Gilteritinib and Quizartinib. FLTi as maintenance in post-transplant patients significantly improved OS [ HR; 0.56] 95% CI [0.46-0.68], P< 0.00001, I2 31%], RFS [HR 0.56; 95% CI (0.50-0.64), P< 0.00001, I2 0%] and LFS [HR 0.47; 95% CI (0.38-0.57), P< 0.00001, I2 0%] as compared to control.

CONCLUSION:

This meta-analysis demonstrates the efficacy of FLT3i as a post-transplant maintenance therapy for preventing relapse in AML patients.

Disclosures: No relevant conflicts of interest to declare.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH